

# ALS register swabia

<https://neurodegenerationresearch.eu/survey/als-register-swabia/>

## **Title of the register**

ALS register swabia

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Albert

## **Name of Principal Investigator - Last name**

Ludolph

## **Address of institution -Institution**

University of Ulm, Department of Neurology

## **Address of institution - Street address**

Oberer Eselsberg 45

## **Address of institution - City**

Ulm

## **Address of institution - Postcode**

89081

## **Country**

Germany

## **Website**

[www.uniklinik-ulm.de/struktur/kliniken/neurologie.html](http://www.uniklinik-ulm.de/struktur/kliniken/neurologie.html)

## **Contact email**

[albert.ludolph@uni-ulm.de](mailto:albert.ludolph@uni-ulm.de)

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Motor neurone diseases

**Q2. In a single sentence, what is the stated aim of your register?**

Epidemiology of ALS in Swabia and Germany

**Q2b. What distinguishes this register from other disease registers?**

**Q3a. i) Number of publications that involve use of your register to date**

0

**Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available?**

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the register**

**Q4a. Study criteria: what is the age range of participants? Age in years: from**

18

**Q4a. Study criteria: what is the age range of participants? Age in years: to**

until death

**Q4b. Study criteria: what are the inclusion criteria?**

DD Motoneuron disease

**Q4c. Study criteria: what are the exclusion criteria?**

other than DD Motoneuron disease

**Q5. What is the size of the register (i.e. how many patients have been enrolled)?**

1001-5000 clinical cases

**Q6a. Please describe what measures are used to characterise participants**

clinical, EMG, MRI, CSF, blood

**Q6b. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

No

**If YES, please describe**

**Q7a. i) Is the register of fixed duration?**

Yes

**Q7a. ii) Please enter the data collection start date**

01/01/1997

**Q7a. iii) Please enter the data collection end date**

**Q7b. Could you provide some information about the data collection for this register?**

Data collection ongoing

**Q8. Funding of the register - How is the register funded?**

**Q8. Funding of the register - Is this funding expected to continue**

**Q8. Funding of the register - If so, for how long (months)?**

**Q9. Could you provide information about data sweeping? - How many data sweeps have taken place?**

**Q9. Could you provide information about data sweeping? - When was the most recent data sweep?**

**Q9. Could you provide information about data sweeping? - When is the next data sweep?**

**Q9. Could you provide information about data sweeping? - How many more data sweeps are planned on current funding? e.g 0,1,2.....**

**Q9. Could you provide information about data sweeping? -How many more data sweeps are planned in total (with funding and with funding yet to be secured) e.g. 0,1,2...**

**Q10. Is the clinical (phenotypic) information that is held in the register from patients and other participants such as family members:**

**Q11. Is there a limit on the number of studies that can be based on this set of patients?**

No

**If YES, please give details**

**Q12a. Please give information on the format and availability of data stored in a database (1)**

% Available

**Q12a. Please give information on the format and availability of data stored in a database (2)**

% Available

**Q12a. Please give information on the format and availability of data stored in a database (3)**

% Available

**Q12a. Please give information on the format and availability of data stored in a database (4)**

% Available

**Q12a. Please give information on the format and availability of data stored in a database (5)**

% Available

**Please specify language used**

**Q12b. Please give information on how data is held as individual records (1)**

% Available

**Q12b. Please give information on how data is held as individual records (2)**

% Available

**Q12b. Please give information on how data is held as individual records (3)**

% Available

**Q12b. Please give information on how data is held as individual records (4)**

% Available

**Please specify language used**

**Q13a. Is data available to other groups?**

Yes

**Q13b. If data is available to other groups what is the access policy/mechanisms for access?**

CONSTITUTION AND BY-LAWS OF THE ALS NETWORK

**Q14. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q15a. Are tissues/samples/DNA available to other groups?**

Yes

**Q15b. i) If yes, please describe below:**

CONSTITUTION AND BY-LAWS OF THE ALS NETWORK

**Q15b. ii) In what form are tissues/samples/DNA supplied?**

**Q15b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q13b above)?**

**Q16a. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of patients**

**% of total cohort**

**Q16b. If yes, is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q13b above)?**

Yes

**Types:**

Disease Registers

**Member States:**

Germany

**Diseases:**

Motor neurone diseases

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A